https://www.ciclomed.com/home daily 1.0 2018-04-17 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516672046752-4CRMFZ2N81JIUPVRI73O/Banner+Image.jpg Home Aiming to Improve Outcomes in Bladder Cancer https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516672086675-P8II9MP6ZPJT1WBB59UB/Banner+Image.jpg Home Developing A Novel Agent for a Serious Unmet Need https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516672179245-7STDAJWF62Y6APA37JQS/Banner+Image.jpg Home Transforming Cancer Care Through Innovation https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516730133946-S3G8D3RVRTRB88CV5DZ8/vials+700.png Home - Learn about our novel anticancer agent Learn about our novel anti-cancer agent https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516726633877-DZN6X5GQMQC5M4GS8TA2/news+blue+700.png Home - Explore news and scientific publications Explore news and scientific publications https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516730018545-8LZZ8VEQ7MM2HMZ2LPM4/People.png Home - Meet CicloMed’s world-class team Meet CicloMed’s world-class team https://www.ciclomed.com/news daily 0.75 2022-05-24 https://www.ciclomed.com/team daily 0.75 2018-01-23 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516675003924-O9AQ85044I0JXKY57Z42/Unknown-6.jpeg Team B https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516735619310-Y9EZMP079VPK2ERNQNO5/Unknown-6.jpeg Team B https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516675045643-STZ908NBDT1RR4MBRTTH/Unknown-8.jpeg Team B https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516735016828-00UD7L957TV63MZDSN42/Unknown.jpeg Team B https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516735213217-G4ISOND7IUH3V8YKVNZD/Unknown-1.jpeg Team B https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516675076086-ABLJGFGK0J43KYADWO7Y/Unknown.png Team B https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516675026003-FW3PNEJFP8MFHUOX61LD/Unknown-7.jpeg Team B https://www.ciclomed.com/lead-product daily 0.75 2020-08-12 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516722885394-SXBES8C4XKOXDSEMCDZ7/shutterstock_450208219.jpg Lead Product https://www.ciclomed.com/contact daily 0.75 2020-09-10 https://www.ciclomed.com/about daily 0.75 2021-12-01 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1516820776358-TISDA67OSY7P2JY6XXYW/CicloMed.png About https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1597245851112-VGVOP45VMJ6BH63YCV0A/Bladder+Cancer+Facts.png About https://www.ciclomed.com/team-2 daily 0.75 2019-12-04 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519398463267-LOY7NIJS2NXTXRLI2EWA/Unknown.png Management Team Scott J. Weir, Pharm.D., Ph.D. Acting Chief Scientific Officer Dr. Weir brings 32 years of drug discovery and development experience to CicloMed. He is a professor at the University of Kansas Medical Center, Director of the Institute for Advancing Medical Innovation (IAMI) at KU, and Associate Director of Translational Research for The University of Kansas Cancer Center. He is a co-discoverer of Ciclopirox Prodrug, the anticancer agent that CicloMed is developing. Since joining KU in 2006, Dr. Weir has established and managed a fully integrated program to discover promising new agents for the treatment and prevention of cancer, and to advance potential new drugs discovered at the university from bench to bedside. From 1986 to 2006, Dr. Weir served in leadership positions in several global pharmaceutical companies, contributing to successful development and regulatory approvals for a number of drug products. He earned his Pharm.D. degree from the University of Nebraska College of Pharmacy, followed by a Ph.D. in pharmacokinetics and biopharmaceutics from the University of Nebraska Medical Center. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1518797973244-1KM5JHHDOG2C2M95A4SP/Unknown-1.jpeg Management Team William McCulloch, M.B., Ch.B., F.R.C.P., F.F.P.M. Acting Chief Medical Officer and Chair of the Clinical Advisory Board Dr. McCulloch brings to his role as CicloMed’s Chief Medical Officer more than three decades of experience in pharmaceutical research and development, as an executive and consultant to large and small companies focusing on cancer and serious infectious diseases. He has undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, securing Orphan Drug status for compounds, and obtaining SBIR and other grant funding. As co-founder and president of Alba BioPharm Advisors since 2002, Dr. McCulloch has provided consulting services in drug development, oncology and regulatory affairs for clients. He earned his medical degree at the University of Glasgow and practiced medicine in the United Kingdom for seven years before entering the industry. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1569066202148-FXP5OPVHGNKMETCYIRYJ/DeBruce%2BHeadshot%2Bpt20356.jpg Management Team Tammy Ham Chief Executive Officer As President and CEO of CicloMed LLC, Ms. Ham leads a team of experts committed to developing and commercializing an innovative, less-invasive approach to fighting bladder cancer. Since 2015 she has served as President and CEO of CicloMed’s parent company, BioNovus Innovations LLC, which is building a portfolio of organizations to advance scientific discoveries into transformational improvements in healthcare. She is also an angel investor. Ms. Ham started her career as a Registered Nurse in hospitals and outpatient settings, then became a clinical administrator. In 1997, she founded Ambulatory Surgery Assistance, Inc., which developed more than 30 ambulatory surgery centers. After selling that company to Nueterra Healthcare in 2005, Ms. Ham served as President of Nueterra Healthcare International. She is a Registered Nurse graduate of Saint Luke’s College of Nursing. Ms. Ham also serves as a mentor with Techstars and a board member of Operation Breakthrough. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519397716901-WBZ7MDAG6UQ9VWI64P0V/square_wood.jpg Management Team Robyn Wood, B.G.S. Project Manager Ms. Wood has over 30 years of drug development experience and has worked since 2009 as project director for the Institute for Advancing Medical Innovation (IAMI) at the University of Kansas Medical Center. A University of Kansas alumna, she spent 17 years with INTERx Research/Merck as a Research Biologist, later moving to Oread Pharmaceuticals and Quintiles. At Quintiles, Ms. Wood was hired as the first project manager to support drug development projects and while there she moved into a senior director position. When Aptuit acquired the early drug development business of Quintiles, she moved from director of pharmaceutical services project manager to global director of client services for Aptuit. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519075075882-4B3VIUF9B555SVASAT1P/Mike_Dalton.jpg Management Team Mike Dalton, Pharm.D. Chief Regulatory Officer Dr. Dalton has more than 25 years of experience in clinical development and regulatory affairs, assisting pharmaceutical and biotech clients in all phases of regulatory strategy development. He is a founding partner of The Gnomon Group. In his consulting capacity and previous positions with Burroughs Wellcome, GlaxoWellcome, PharmaResearch and Triangle/Gilead, he has had a leadership role in at least 15 NDA approvals and many supplemental NDAs, as well as helping file more than 50 INDs and serving as FDA contact and liaison. He has also served as head of pharmacovigilance at several companies and advises companies on drug safety. Dr. Dalton earned a bachelor’s degree from the University of Nebraska at Omaha School of Pharmacy and a Pharm.D. from the University of Michigan. He completed a clinical fellowship with the University of North Carolina at Chapel Hill School of Pharmacy and Burroughs Wellcome Company in Research Triangle Park. He also served as an officer in the U.S. Army and worked as a staff pharmacist at Veterans Administration hospitals. https://www.ciclomed.com/team-1 daily 0.75 2019-12-04 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519398422960-6NFOEVZS6X92D0D0ETPV/square_mcc.jpg Clinical Advisors Michael S. Cookson, M.D. Member, Clinical Advisory Board A nationally recognized researcher and lecturer in urologic oncology, Dr. Cookson serves as Professor and Chairman of the Department of Urology at the University of Oklahoma Health Sciences Center. He is the author of 211 peer-reviewed journal publications and 29 chapters of textbooks in urology and urologic surgery. He completed his urology residency at the University of Texas, San Antonio and his Urologic Oncology Fellowship at Memorial Sloan Kettering Cancer Center in New York. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1518278148842-ZNLXO0PPKNWAQNERXA2E/Unknown-3.jpeg Clinical Advisors Gary Steinberg, M.D. Member, Clinical Advisory Board Dr. Steinberg specializes in urologic oncology. He serves as Bruce and Beth White Family Professor, Professor of Surgery and Director, Urologic Oncology at the University of Chicago Medicine and its Duchossois Center for Advanced Medicine. Dr. Steinberg has more than 25 years of expertise in developing innovative surgical procedures for patients with bladder, kidney, testicular and prostate cancers; performing continent urinary reconstructions in patients who have their bladders removed due to cancer; and performing robotic-assisted laparoscopic radical cystectomies. Dr. Steinberg is also the chairperson of the scientific advisory board of the Bladder Cancer Advocacy Network and the executive committee of the Bladder Cancer Research Network. He was trained at the University of Chicago Pritzker School of Medicine and completed his internship, residency and fellowship at Johns Hopkins University. He is also a member of American College of Surgeons, American Society of Clinical Oncology, American Urologic Association, Chicago Urologic Society, Illinois State Urological Society, and Society of Urologic Oncology. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575490185117-AUF9UJCH5OLZQ483F7M9/Noah+Hahn+1.jpg Clinical Advisors Noah M. Hahn, M.D. Dr. Hahn is Director of the Medical Oncology Bladder Cancer Program and Associate Professor of Oncology and Urology at the Johns Hopkins University School of Medicine. He is an internationally recognized authority in the conduct of bladder cancer novel therapeutic clinical trials and translational investigations, and one of the few oncologists in the world leading a clinical trial in non-muscle invasive bladder cancer. After graduating from the University of Notre Dame with a degree in mechanical engineering, he earned his M.D. degree in 2000 at the Indiana University School of Medicine. He completed an internship at Emory University, internal medicine residency at Duke University, and an hematology and oncology fellowship at the Indiana University Simon Cancer Center (IUSCC). He then joined the IUSCC oncology faculty and served as the leader of its prostate and bladder cancer programs. Dr. Hahn joined Johns Hopkins in 2014. He also serves as bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), co-chairs the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participates on the NCI Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1518882044117-5X97XOXKQJMRMSJQZANH/2017+Headshot_Burris.jpg Clinical Advisors Howard A. "Skip" Burris, III, M.D. Principal Investigator As President of Clinical Operations and Chief Medical Officer of Sarah Cannon, HCA’s global cancer care and research organization, Dr. Burris leads clinical strategy and drug development initiatives, including overseeing physician-led, patient-centric integrated cancer care. He is serving as Principal Investigator for the Phase I clinical trial of Ciclopirox Prodrug. Dr. Burris practices medicine with Tennessee Oncology, PLLC. He has authored more than 350 publications and more than 550 abstracts. He earned his medical degree from the University of South Alabama and performed his residency and fellowship in hematology/oncology at Brooke Army Medical Center. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519398382765-IJR9WQGT9CRRZMN90EAP/square_taylor.jpg Clinical Advisors John A. Taylor III, M.D., M.C.T.S. Member, Clinical Advisory Board Dr. Taylor is a board-certified urologist and nationally recognized expert on bladder cancer. His work has been recognized by multiple peer-reviewed publications and several U.S. provisional/full patents. He joined the University of Kansas Medical Center in 2016 and serves as a Professor, Director of Basic Urologic Research and Co-Leader of the D3ET Program. He will serve as Principal Investigator for clinical trials in muscle invasive and non-muscle invasive bladder cancer patients. Dr. Taylor also founded and serves as President and Director of the Leo & Anne Albert Institute for Bladder Cancer Care and Research. He earned his medical degree at Columbia University’s College of Physicians & Surgeons, where he also completed his internship and residency in general surgery and urology. He served three years on active duty at Walter Reed Army Medical Center and was Director of Medical Education for Urology and Assistant Professor at USUHS. He then took a faculty position at the University of Connecticut Health Center, and while there completed a Master’s in Clinical and Translation Science. Dr. Taylor runs a translational research laboratory focused on identification and development of novel compounds for the treatment of bladder cancer. He participates regularly on national and international committees to develop standards for bladder cancer care and has served on the AUA’s research council, the NIH/NCI Bladder Cancer Task Force for Clinical Trial Development and as an ad hoc member of the FDA’s Oncologic Drug Advisory Committee. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1518797973244-1KM5JHHDOG2C2M95A4SP/Unknown-1.jpeg Clinical Advisors William McCulloch, M.B., Ch.B., F.R.C.P., F.F.P.M. Chief Medical Officer and Chair of the Clinical Advisory Board Dr. McCulloch brings to his role as CicloMed’s Chief Medical Officer more than three decades of experience in pharmaceutical research and development, as an executive and consultant to large and small companies focusing on cancer and serious infectious diseases. He has undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, securing Orphan Drug status for compounds, and obtaining SBIR and other grant funding. As co-founder and president of Alba BioPharm Advisors since 2002, Dr. McCulloch has provided consulting services in drug development, oncology and regulatory affairs for clients. He earned his medical degree at the University of Glasgow and practiced medicine in the United Kingdom for seven years before entering the industry. https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519398405748-CQNRTLYPDQ2UT8NJ5QRK/square_holzerbein.jpg Clinical Advisors Jeffrey Maxwell Holzbeierlein, M.D., F.A.C.S. Member, Clinical Advisory Board Dr. Holzbeierlein is a Professor of Urology, Director of Urologic Oncology and Chair of the Department of Urology at the University of Kansas Medical Center. He also serves as Director of KU’s Burns and McDonnell High Risk Prostate Cancer Prevention and Survivorship Clinic, and Chair of the Surgical Oncology Committee. He completed his medical degree at the University of Oklahoma, internship and residency at Vanderbilt University, and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He is a Fellow of the American College of Surgeons. Dr. Holzbeierlein serves as Chair of ASCO’s Genitourinary Program Committee and Vice Chair of ASCO’s Muscle Invasive Bladder Cancer Guidelines Committee, as well as numerous other professional boards and committees. https://www.ciclomed.com/test-download daily 0.75 2018-06-07 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1528384339971-WFGL3G0K53OC33DCVA5A/Hero.jpg Test download https://www.ciclomed.com/form daily 0.75 2018-06-07 https://www.ciclomed.com/william daily 0.75 2019-12-05 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575556706761-4CFA5BYDKP08KXSNOBR5/Unknown-11.jpeg William https://www.ciclomed.com/howard daily 0.75 2019-12-05 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575556674600-ROJE2MPMORTG6DKGAMLW/2017+Headshot_Burris.jpg Howard https://www.ciclomed.com/john daily 0.75 2019-12-05 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575556580025-PANA83KI4RRK23UIDTI6/Unknown-7.jpeg John https://www.ciclomed.com/gary daily 0.75 2019-12-05 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575556502611-PNW9A3VCVLI0PEJ1M3N5/Unknown-3.jpeg Gary https://www.ciclomed.com/jeff daily 0.75 2019-12-05 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575556456258-WB2A74ID8J6VMUPQP47N/jholzbeierlein.jpg Jeff https://www.ciclomed.com/mike daily 0.75 2019-12-05 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575556415448-XBYQ32TJETJFJSYEXE98/square_mcc.jpg Mike https://www.ciclomed.com/noah daily 0.75 2019-12-04 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575499550088-FS64OTTWR6PZ4JHJRVJ5/Noah+Hahn+1.jpg Noah https://www.ciclomed.com/clinical-advisors daily 0.75 2019-12-05 https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519398382765-IJR9WQGT9CRRZMN90EAP/square_taylor.jpg Copy of Clinical Advisors John A. Taylor III, M.D., M.C.T.S. Member, Clinical Advisory Board https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519398405748-CQNRTLYPDQ2UT8NJ5QRK/square_holzerbein.jpg Copy of Clinical Advisors Jeffrey Maxwell Holzbeierlein, M.D., F.A.C.S. Member, Clinical Advisory Board https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1575490185117-AUF9UJCH5OLZQ483F7M9/Noah+Hahn+1.jpg Copy of Clinical Advisors Noah M. Hahn, M.D. Member, Clinical Advisory Board https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1518882044117-5X97XOXKQJMRMSJQZANH/2017+Headshot_Burris.jpg Copy of Clinical Advisors Howard A. "Skip" Burris, III, M.D. Principal Investigator https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1518278148842-ZNLXO0PPKNWAQNERXA2E/Unknown-3.jpeg Copy of Clinical Advisors Gary Steinberg, M.D. Member, Clinical Advisory Board https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1518797973244-1KM5JHHDOG2C2M95A4SP/Unknown-1.jpeg Copy of Clinical Advisors William McCulloch, M.B., Ch.B., F.R.C.P., F.F.P.M. Chief Medical Officer and Chair of the Clinical Advisory Board https://images.squarespace-cdn.com/content/v1/5a667f806957dad4d1b2d63b/1519398422960-6NFOEVZS6X92D0D0ETPV/square_mcc.jpg Copy of Clinical Advisors Michael S. Cookson, M.D. Member, Clinical Advisory Board https://www.ciclomed.com/conflict-of-interest-policy daily 0.75 2020-12-08 https://www.ciclomed.com/video daily 0.75 2022-05-11 https://www.ciclomed.com/home-alt-bedford daily 0.75 2025-05-12 https://images.squarespace-cdn.com/content/v1/52a74d9ae4b0253945d2aee9/1390500612440-PGQSIY8KL9F7T5VIXQLO/chambers-2.jpg Home Alt A better world Starts with a choice Contact Us https://images.squarespace-cdn.com/content/v1/52a74d9ae4b0253945d2aee9/1390500503574-5BAPXZO9U06UV61P49UO/chambers1.jpg Home Alt Sustainability Starts with you Join Us https://images.squarespace-cdn.com/content/v1/52a74d9ae4b0253945d2aee9/1390500933384-LII4SRIPHFYOUFX0UCXC/chambers-4.jpg Home Alt A better world Starts with a choice Join Us https://images.squarespace-cdn.com/content/v1/52a74d9ae4b0253945d2aee9/1390504287124-HQ8GNX1JCE22V047MSQ9/chambers-8.jpg Home Alt Preserve Nature Join Us